NASDAQ:PGNX - Progenics Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Progenics Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $3.80 +0.11 (+2.98 %) (As of 03/31/2020 04:00 PM ET) Add Compare Today's Range$3.60Now: $3.80▼$3.8850-Day Range$2.11MA: $4.07▼$5.1652-Week Range$1.89Now: $3.80▼$6.37Volume628,343 shsAverage Volume977,194 shsMarket Capitalization$329.07 millionP/E RatioN/ADividend YieldN/ABeta2.3 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Progenics Pharmaceuticals, Inc., an oncology company, develops, manufactures, and commercializes pharmaceutical products and other technologies to target, diagnose, and treat cancer cancer in the United States and internationally. The company's product candidates include Azedra, a radiotherapeutic product candidate for the treatment of iobenguane scan positive, unresectable, and locally advanced or metastatic pheochromocytoma or paraganglioma for adult and pediatric patients; PyL, a clinical-stage fluorinated prostate specific membrane antigen (PSMA)-targeted PET/CT imaging agent for prostate cancer; and 1095, a PSMA-targeted Iodine-131 labeled small molecule, which is in Phase II clinical trial for the treatment of metastatic castration-resistant prostate cancer. Its product candidates also comprise PSMA TTC, a thorium-227 labeled PSMA-targeted antibody therapeutic that is in Phase I clinical trial for treatment of metastatic prostate cancer; and Leronlimab, a humanized monoclonal antibody, which is in Phase III development for the treatment of HIV infection. The company also offers Relistor-subcutaneous injection for the treatment of opioid-induced constipation (OIC) in adults with chronic non-cancer pain or advanced-illness adult patients; Relistor tablets for the treatment of OIC in adults with chronic non-cancer pain; PSMA AI, an imaging analysis technology that uses artificial intelligence and machine learning to quantify and automate the reading of PSMA targeted imaging; and automated bone scan index, a software that quantifies the hotspots on bone scans and calculates the bone scan index value. It has license agreement with Salix Pharmaceuticals, Inc. for the development and commercialization of Relistor worldwide; and Amgen Fremont, Inc. to use its XenoMouse technology for generating human antibodies to PSMA. Progenics Pharmaceuticals, Inc. was founded in 1986 and is based in New York City, New York.Read More Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:PGNX Previous Symbol CUSIP74318710 CIK835887 Webhttp://www.progenics.com/ Phone646-975-2500Debt Debt-to-Equity Ratio1.01 Current Ratio2.89 Quick Ratio2.89Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$34.99 million Price / Sales9.40 Cash FlowN/A Price / Cash FlowN/A Book Value$0.54 per share Price / Book7.04Profitability EPS (Most Recent Fiscal Year)($0.80) Net Income$-68,550,000.00 Net Margins-195.94% Return on Equity-106.04% Return on Assets-48.40%Miscellaneous Employees79 Outstanding Shares86,597,000Market Cap$329.07 million Next Earnings Date5/14/2020 (Estimated) OptionableOptionable Receive PGNX News and Ratings via Email Sign-up to receive the latest news and ratings for PGNX and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:PGNX Rates by TradingView Progenics Pharmaceuticals (NASDAQ:PGNX) Frequently Asked Questions How has Progenics Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)? Progenics Pharmaceuticals' stock was trading at $3.81 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, PGNX stock has decreased by 0.3% and is now trading at $3.80. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Progenics Pharmaceuticals? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Progenics Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Progenics Pharmaceuticals. When is Progenics Pharmaceuticals' next earnings date? Progenics Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, May 14th 2020. View our earnings forecast for Progenics Pharmaceuticals. How were Progenics Pharmaceuticals' earnings last quarter? Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) posted its earnings results on Friday, March, 13th. The biotechnology company reported ($0.13) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.25) by $0.12. The biotechnology company earned $15.13 million during the quarter. Progenics Pharmaceuticals had a negative net margin of 195.94% and a negative return on equity of 106.04%. View Progenics Pharmaceuticals' earnings history. What price target have analysts set for PGNX? 3 equities research analysts have issued twelve-month target prices for Progenics Pharmaceuticals' shares. Their forecasts range from $10.00 to $14.00. On average, they anticipate Progenics Pharmaceuticals' stock price to reach $12.00 in the next twelve months. This suggests a possible upside of 215.8% from the stock's current price. View analysts' price targets for Progenics Pharmaceuticals. Has Progenics Pharmaceuticals been receiving favorable news coverage? News coverage about PGNX stock has trended positive on Tuesday, InfoTrie reports. InfoTrie rates the sentiment of media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Progenics Pharmaceuticals earned a news sentiment score of 3.0 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news aboutProgenics Pharmaceuticals. Are investors shorting Progenics Pharmaceuticals? Progenics Pharmaceuticals saw a drop in short interest in February. As of February 28th, there was short interest totaling 5,430,000 shares, a drop of 10.1% from the February 13th total of 6,040,000 shares. Based on an average daily trading volume, of 893,100 shares, the short-interest ratio is presently 6.1 days. Approximately 7.0% of the company's stock are sold short. View Progenics Pharmaceuticals' Current Options Chain. Who are some of Progenics Pharmaceuticals' key competitors? Some companies that are related to Progenics Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL). What other stocks do shareholders of Progenics Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Progenics Pharmaceuticals investors own include Vonage (VG), Synergy Pharmaceuticals (SGYP), Exelixis (EXEL), Caterpillar (CAT), Novavax (NVAX), Imax (IMAX), Opko Health (OPK), Cara Therapeutics (CARA), Portola Pharmaceuticals (PTLA) and Dynavax Technologies (DVAX). Who are Progenics Pharmaceuticals' key executives? Progenics Pharmaceuticals' management team includes the following people: Mr. Mark R. Baker, CEO & Director (Age 64)Mr. Patrick Fabbio, Exec. VP & CFO (Age 51)Mr. Benedict Osorio, Chief Operating Officer (Age 62)Dr. Vivien Wong, Exec. VP of Devel. (Age 62)Mr. Bryce V. Tenbarge, Sr. VP of Commercial (Age 46) What is Progenics Pharmaceuticals' stock symbol? Progenics Pharmaceuticals trades on the NASDAQ under the ticker symbol "PGNX." How do I buy shares of Progenics Pharmaceuticals? Shares of PGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Progenics Pharmaceuticals' stock price today? One share of PGNX stock can currently be purchased for approximately $3.80. How big of a company is Progenics Pharmaceuticals? Progenics Pharmaceuticals has a market capitalization of $329.07 million and generates $34.99 million in revenue each year. The biotechnology company earns $-68,550,000.00 in net income (profit) each year or ($0.80) on an earnings per share basis. Progenics Pharmaceuticals employs 79 workers across the globe. View additional information about Progenics Pharmaceuticals. What is Progenics Pharmaceuticals' official website? The official website for Progenics Pharmaceuticals is http://www.progenics.com/. How can I contact Progenics Pharmaceuticals? Progenics Pharmaceuticals' mailing address is ONE WORLD TRADE CENTER 47TH FLOOR, NEW YORK NY, 10007. The biotechnology company can be reached via phone at 646-975-2500 or via email at [email protected] MarketBeat Community Rating for Progenics Pharmaceuticals (NASDAQ PGNX)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 410 (Thanks for Voting!)Underperform Votes: 373 (Thanks for Voting!)Total Votes: 783MarketBeat's community ratings are surveys of what our community members think about Progenics Pharmaceuticals and other stocks. Vote "Outperform" if you believe PGNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PGNX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/31/2020 by MarketBeat.com StaffFeatured Article: Moving Average Convergence Divergence (MACD)
